Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio
03:01am, Monday, 27'th Apr 2026
GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed a counterclaim brought by AnaptysBio, the US biotechnology company, in a
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
03:40pm, Friday, 24'th Apr 2026
Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reduction Trial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against Te
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
03:40pm, Friday, 24'th Apr 2026
SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announ
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
09:15am, Monday, 20'th Apr 2026
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its f
AnaptysBio (NASDAQ:ANAB) Director John Schmid Sells 20,645 Shares of Stock
04:48am, Friday, 03'rd Apr 2026
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) Director John Schmid sold 20,645 shares of the firm's stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $56.1
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
09:00am, Friday, 27'th Mar 2026
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. (“First Tracks Bio”), and EcoR1 Capital
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
09:00am, Friday, 27'th Mar 2026
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
09:00am, Friday, 27'th Mar 2026
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has approved the previously announced spin-off of First Tracks Biotherapeutics
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
11:20am, Tuesday, 10'th Mar 2026
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
AnaptysBio, Inc. $ANAB Shares Sold by Citigroup Inc.
04:36am, Sunday, 08'th Mar 2026
Citigroup Inc. cut its position in shares of AnaptysBio, Inc. (NASDAQ: ANAB) by 93.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates
06:35pm, Tuesday, 03'rd Mar 2026
AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to a loss of $0.72 per share a year ago.
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
04:15pm, Tuesday, 03'rd Mar 2026
Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac di
WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics Li
Anaptys Announces Participation at Upcoming Investor Conferences
04:15pm, Thursday, 05'th Feb 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
FMB WEALTH MANAGEMENT Buys 5,592 Shares of AnaptysBio Inc (ANAB)
09:12am, Thursday, 22'nd Jan 2026
Summary FMB WEALTH MANAGEMENT initiated a new position in AnaptysBio Inc(ANAB), purchasing 5,592 shares valued at approximately $271,100 as of its late
